Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis

M. Villar, G. Sotgiu, L. D'Ambrosio, E. Raymundo, L. Fernandes, J. Barbedo, N. Diogo, C. Lange, R. Centis, G.B. Migliori
European Respiratory Journal 2011 38: 730-733; DOI: 10.1183/09031936.00195210
M. Villar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Sotgiu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. D'Ambrosio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Raymundo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. Fernandes
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Barbedo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. Diogo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Lange
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Centis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G.B. Migliori
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: giovannibattista.migliori@fsm.it
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editors:

Treatment of multidrug-resistant (MDR) tuberculosis (TB) (defined as in vitro resistance to at least isoniazid and rifampicin, the two most potent first-line drugs for TB treatment) and extensively drug-resistant (XDR)-TB (defined as in vitro resistance to isoniazid and rifampicin plus any fluoroquinolone and at least one of the injectable drugs: amikacin, capreomycin or kanamycin) is still a major problem from both a clinical and a public health perspective [1–5].

Treatment outcomes for complicated MDR-TB cases (those with additional resistance beyond isoniazid and rifampicin) and XDR-TB cases being still poor, the need for information on the safety, tolerability and efficacy of other antibiotics that are potentially useful in their treatment is urgent [6–9].

In vitro and pharmacological data suggest that linezolid, an oxazolidinone antibiotic, could be useful in treating mycobacterial infections, including MDR-TB [9–11]. However, clinical experience with the off-label use of linezolid is still limited to case reports and small case series involving nontuberculous mycobacterial diseases [12] and TB, the four largest cohorts including 10 [13], 12 [14], 30 [15] and 85 cases (but only 45 with information on efficacy) [9], respectively. The aim of this study was to evaluate the safety, tolerability and efficacy of linezolid in a cohort of patients with MDR/XDR-TB from Portugal.

Clinical information necessary to study safety, tolerability and efficacy was prospectively collected on all MDR-TB cases treated with linezolid in Portugal between 2004 and 2009, with the exception of one case who started the treatment in 2003 (whose information was collected retrospectively). The protocol was designed to be compatible with that used to study the largest cohort available [9]. Internationally agreed outcome definitions were used [9].

In particular, a patient who completed treatment and was consistently culture-negative with at least five results for the final 12 months of treatment was defined as cured. If bacteriological results were lacking (i.e. <5 cultures performed), the case was defined as treatment completed. Treatment failure was defined as two or more positive cultures in the previous 12 months of treatment, or if a medical decision was made to terminate treatment due to poor response or adverse events. Definitions of other treatment outcomes (i.e. death, default and transfer) were the same as previously used in the European study on linezolid efficacy, safety and tolerability [9].

Approval for collection of study data was provided by the ethical committee of the coordinating centre [9], the participating hospitals complying with national regulations and organisational requirements for protection of human subjects. All data were coded and individual identifiers were available only to treating physicians.

Safety and tolerability end-points included major and minor side-effects. A major side-effect was defined as any adverse reaction that resulted in temporary or permanent discontinuation of linezolid, while a minor side-effect required only dose adjustment and/or addition of concomitant treatment.

Efficacy end-points included time to and proportion of sputum smear and culture conversions, and treatment outcome. Sputum conversion was defined as two consecutive negative sputum smears in patients who were sputum smear-positive at diagnosis. Time to culture conversion was defined as time from treatment start to date of the first of two consecutive negative cultures.

Drug susceptibility testing (DST) for all first- and second-line anti-TB drugs was performed by the Supranational Reference Laboratory in Porto, Portugal (quality-assured within the World Health Organization (WHO) proficiency scheme) [1, 2]. All participating centres performed sputum smear examinations weekly until negative, and then monthly. Cultures were performed monthly.

Regimens to treat MDR/XDR-TB cases were tailored to DST results according to WHO recommendations, using fluoroquinolones, injectable agents and other second-line oral agents co-administered with linezolid in all individuals. Linezolid was available without any limitation, and was prescribed at the dose of 1,200 mg once daily to 15 cases except one, who received 600 mg once daily.

The study end-points have been compared with those of the two largest series, including only patients with a definitive treatment outcome in the efficacy analyses (cure, failure and death) [9, 15].

Categorical variables were compared using the Chi-squared test and continuous variables by the t-test, or Wilcoxon–Mann–Whitney for unpaired data. A p-value of ≤0.05 was considered statistically significant. Data were collected on standardised e-forms and analysed using Stata 9.0 (StataCorp, College Station, TX, USA).

The main results are summarised in table 1. 16 cases were analysed, 12 (75%) being affected by XDR-TB strains. 12 (75%) were males, with a mean±sd age of 34.8±10 yrs. Five (31.3%) were foreign-born immigrants (three from Cape Verde, one from Angola and one from Guinea-Bissau, respectively). Six (37.5%) were HIV seropositive, all of them being treated with anti-retroviral drugs. 12 (75%) of them were affected by pulmonary and four had simultaneous extrapulmonary forms (three pleural and one lymph node TB, respectively) of culture-positive disease. Three (18.8%) cases underwent surgical interventions (pleurectomy, lobectomy and pneumonectomy, respectively). The median duration of hospital stay in the cohort was 82 days (interquartile range (IQR) 34–152 days).

View this table:
  • View inline
  • View popup
Table 1– Sociodemographic and clinical characteristics of 16 multidrug-/extensively drug-resistant tuberculosis patients exposed to linezolid

Out of 16 cases, nine completed their treatment (eight cured, one died), one defaulted at month 20 after achieving sputum smear and culture conversion, and six were still on treatment at the time of the analysis (four out of six having converted both sputum smear and culture after an average time of 275 and 650 days, respectively).

Linezolid was administered for a median (IQR) period of 375 days (270–630 days).

Three (18.8%) cases experienced adverse events, including anaemia, pancytopenia and polyneuropathy, after 30, 63 and 60 days of drug exposure, respectively.

Comparing the main outcomes with those of the main series (table 2), we observed no difference in successful treatment outcomes (89% in this study versus 80% in the European cohort [9] and 96% in the cohort of Schecter et al. [15], p-value not significant).

View this table:
  • View inline
  • View popup
Table 2– comparison of safety profile and efficacy endpoints in multidrug (MDR)-/extensively drug (XDR)-resistant cases with definite outcome from Portugal versus other major cohorts

The median time to sputum smear and culture conversion was shorter in the European study than in the present study (76 versus 150 days, p = 0.07; and 108 versus 180 days, p = 0.02, respectively).

The proportion of major adverse events was significantly lower in Portugal than in the European cohort [9] (one out of 16 versus 27 out of 85; p = 0.03) but not significantly different if compared with that recorded in the USA (one out of 16 versus three out of 30; p = 0.65) [15].

No significant difference was found when the comparison for minor adverse events was performed.

The regimens used to treat individual patients and information on bacteriological conversion are summarised in table 3.

View this table:
  • View inline
  • View popup
Table 3– Anti-tuberculosis regimens prescribed to multidrug (MDR)-/extensively drug-resistant tuberculosis (TB) patients in Portugal, 2003–2009

The results of this observational study confirm that under specialised management, treatment success in difficult-to treat MDR-/XDR-TB cases is high, although the proportion of XDR-TB cases (and of HIV-positive) individuals in Portugal is higher than in the other major studies available [9, 15]. Furthermore, a control group of MDR-/XDR-TB patients treated with linezolid-sparing regimens was not analysed. However, the proportion of adverse events (both minor and major) was lower than in previous cohorts, being significant only when comparing major adverse events of the Portuguese cohort versus a European one [9], although a relatively high dose of linezolid (1,200 mg once daily) was used.

The evaluation of safety and tolerability is difficult to perform, as different drugs are included in the treatment regimens (necessarily guided by DST) and the duration of exposure to linezolid, as well as the dosages prescribed (300–1,200 mg), varied among patients and among studies.

Pending larger studies, a meta-analysis including individual data from the patients treated with linezolid will be important to hopefully give the final word on whether this drug could really be considered for wider use outside the few cases affected by strains resistant to more than seven drugs [9].

Footnotes

  • Support Statement

    The study was supported by the current research funds of the participating institutions. For this publication, the research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement FP7-223681.

  • Statement of Interest

    None declared.

  • ©ERS 2011

REFERENCES

  1. ↵
    World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. Publication No. WHO/HTM/TB/2010.3. Geneva, World Health Organization, 2010.
  2. ↵
    World Health Organization. Global tuberculosis control 2010. Publication No. WHO/HTM/TB/2010.7. Geneva, World Health Organization, 2010.
  3. World Health Organization. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 2006; 81: 430–432.
    OpenUrlPubMed
  4. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs – worldwide, 2000–2004. MMWR Morb Mortal Wkly Rep 2006; 55: 301–305.
    OpenUrlPubMed
  5. ↵
    1. Migliori GB,
    2. Besozzi G,
    3. Girardi E,
    4. et al
    . Clinical and operational value of the extensively drug-resistant tuberculosis definition. Eur Respir J 2007; 30: 623–626.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Migliori GB,
    2. Lange C,
    3. Girardi E,
    4. et al
    . Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur Respir J 2008; 31: 904–910.
    OpenUrlFREE Full Text
    1. Migliori GB,
    2. Lange C,
    3. Centis R,
    4. et al
    . Resistance to second-line injectables and treatment outcomes in MDR and XDR-TB cases. Eur Respir J 2008; 31: 1155–1159.
    OpenUrlAbstract/FREE Full Text
    1. Sotgiu G,
    2. Ferrara G,
    3. Matteelli A,
    4. et al
    . Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009; 33: 871–881.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Migliori GB,
    2. Eker B,
    3. Richardson MD,
    4. et al
    . A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34: 387–393.
    OpenUrlAbstract/FREE Full Text
    1. Diekema DJ,
    2. Jones RN
    . Oxazolidinone antibiotics. Lancet 2001; 358: 1975–1982.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Molicotti P,
    2. Ortu S,
    3. Bua A,
    4. et al
    . In vitro efficacy of Linezolid on clinical strains of Mycobacterium tuberculosis and other mycobacteria. New Microbiol 2006; 29: 275–280.
    OpenUrlPubMed
  9. ↵
    1. Ntziora F,
    2. Falagas ME
    . Linezolid for the treatment of patients with atypical mycobacterial infection: a systematic review. Int J Tuberc Lung Dis 2007; 11: 606–611.
    OpenUrlPubMedWeb of Science
  10. ↵
    1. Condos R,
    2. Hadgiangelits N,
    3. Leibert E,
    4. et al
    . Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 2008; 134: 187–192.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Von der Lippe B,
    2. Sandven P,
    3. Brubakk O
    . Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB) – a report of ten cases. J Infect 2006; 52: 92–96.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Schecter GF,
    2. Scott C,
    3. True L,
    4. et al
    . Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010; 50: 49–55.
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 38 Issue 3 Table of Contents
European Respiratory Journal: 38 (3)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis
M. Villar, G. Sotgiu, L. D'Ambrosio, E. Raymundo, L. Fernandes, J. Barbedo, N. Diogo, C. Lange, R. Centis, G.B. Migliori
European Respiratory Journal Sep 2011, 38 (3) 730-733; DOI: 10.1183/09031936.00195210

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis
M. Villar, G. Sotgiu, L. D'Ambrosio, E. Raymundo, L. Fernandes, J. Barbedo, N. Diogo, C. Lange, R. Centis, G.B. Migliori
European Respiratory Journal Sep 2011, 38 (3) 730-733; DOI: 10.1183/09031936.00195210
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Pulmonary endarterectomy in sickle cell haemoglobin C disease
  • Cell count and lymphocyte immunophenotyping of bronchoalveolar lavage fluid in healthy Brazilian children
  • Clinical relevance of mixed respiratory viral infections in adults with influenza A H1N1
Show more Letter

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society